Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466810 | 1.00 | DPP4 (0.69) | DPP4CYP2C19PNMTF10PTGS2 | |
| SCHEMBL2981250 | 0.83 | DPP4 (0.91) | DPP4PNMTHTR7TAAR1NOS3 | |
| SCHEMBL17842280 | 0.82 | NR4A2 (0.49) | DPP4CYP2C19PNMTF10PTGS2 | |
| SCHEMBL29872374 | 0.82 | DPP4 (1.00) | DPP4PNMTHTR7TAAR1 | |
| SCHEMBL469051 | 0.82 | DPP4 (1.00) | DPP4PNMTHTR7TAAR1 | |
| SCHEMBL1497158 | 0.81 | CYP2C19 (0.53) | DPP4CYP2C19PTGS2PTGS1CYP1A2 | |
| SCHEMBL399409 | 0.81 | DPP4 (0.72) | DPP4CYP2C19PNMTMAOBTAAR1 | |
| SCHEMBL1559894 | 0.81 | CYP2C19 (0.49) | DPP4CYP2C19PTGS2PTGS1CYP1A2 | |
| SCHEMBL3789431 | 0.81 | DPP4 (0.72) | DPP4PNMTMAOBTAAR1NOS3 | |
| Hydrochloric Acid SCHEMBL4776720 | 0.80 | DPP4 (0.95) | DPP4PNMTHTR7TAAR1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167479-B1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LTD (IN) | 2013-09-11 | — | — | EP | claimed |
| US-8084606-B2 | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates | SYMED LABS LIMITED (IN) | 2011-12-27 | — | — | US | claimed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | claimed |
| EP-2167479-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2010-03-31 | — | — | EP | claimed |
| US-20090281318-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2009-11-12 | — | — | US | claimed |
| WO-2008152650-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2008-12-18 | — | — | WO | claimed |
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| EP-0617028-B1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl] piperazine | UCB SA (BE) | 2000-06-14 | — | — | EP | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2167479-B1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8350031-B2 | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-5792770-A | ADMINISTERING AS SEDATIVE, TRANQUILIZER, ANXIOLYTIC AGENT | U C B S.A. (BE) | 1998-08-11 | — | — | US | disclosed |
| US-5703082-A | ANTIHISTAMINE; TRANQUILIZERS | U C B S.A. (BE) | 1997-12-30 | — | — | US | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
| US-5278191-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1994-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CYP3A5, CYP4A11, IL5 | DPP4 968/4885CYP2C19 47/4885PNMT 391/4885 |
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | DPP4 25/4885CYP2C19 213/4885PNMT 39/4885 |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | DPP4 26/4885CYP2C19 260/4885PNMT 40/4885 |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | DPP4 26/4885CYP2C19 260/4885PNMT 40/4885 |
| US-20090281318-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | CYP3A5, TPH1, CYP51A1 | DPP4 173/4885CYP2C19 111/4885PNMT 97/4885 |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | DPP4 4212/4885CYP2C19 4726/4885PNMT 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.